Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$150.00K$150.00Kderived−3.8% vs Q4 2023 Net Income-$11.79M-$11.79MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$12,572,000N/M Operating Cash Flowderived-$10,267,000N/M Free Cash Flowderived-$10,267,000N/M Margins · derivedOperating margin-8381.3%−1758.3 pt vs Q4 2023
Net margin-7858.0%−1872.7 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 27, 2025 · 58 d after period end